Medtronic Q4 FY26 GAAP diluted EPS climbs 17.1% to $0.96; revenue increases 9.9% to $9.8 billion

Medtronic

Medtronic

MDT

0.00
  • Medtronic Q4 revenue rose 9.9% to USD 9.8 billion; GAAP diluted EPS climbed 17.1% to USD 0.96.
  • GAAP operating profit jumped 30.4% to USD 1.87 billion; operating margin widened 3 percentage points to 19.1%.
  • FY26 revenue increased 8.4% to USD 36.4 billion; GAAP diluted EPS rose 3.3% to USD 3.73.
  • Cardiac Ablation Solutions revenue more than doubled, up 78% globally; Cardiovascular revenue increased 13.8% to USD 3.8 billion.
  • FY27 organic revenue growth guided at 6.75% to 7.25%; non-GAAP diluted EPS seen at USD 5.90 to USD 6.00.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medtronic plc published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606030645PR_NEWS_USPR_____CG74147) on June 03, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.